Are angiotensin converting enzyme (ACE1/ ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A singlecenter cohort study

Yıl: 2022 Cilt: 26 Sayı: 2 Sayfa Aralığı: 133 - 140 Metin Dili: İngilizce DOI: 10.5152/AnatolJCardiol.2021.502

Are angiotensin converting enzyme (ACE1/ ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A singlecenter cohort study

Öz:
Objective: The impact of the coronavirus disease 2019 (COVID-19) pandemic has been unceasingly ongoing worldwide. Recent bioinformatics analysis and epidemiologic studies have highlighted that the functional polymorphisms on the angiotensin converting enzyme (ACE) gene may have an impact on the clinical progress of COVID-19. In this study, we aimed to determine the impact of the ACE1 gene I/D polymorphism and ACE2 peptidase-2 domain variants on disease severity. Methods: Hundred patients with confirmed COVID-19 related pneumonia [50 patients with severe disease in intensive care unit (ICU) and 50 patients not in ICU] were compared on the basis of genetic and clinical characteristics. Genomic DNA was purified from peripheral blood lymphocytes with an automated QIA symphony DSP DNA Mini-Kit. The Sanger sequencing analysis was performed. The frequencies of ACE1 gene polymorphism and ACE2 PD variants were compared in patients hospitalized in ICU and those not in ICU. The Statistical Package for Social Sciences version 22.0 was used for statistical analysis. Results: The sequencing analysis of the ACE2 gene exon 1 and 2 revealed none of the polymorphisms investigated or any other variants in the present cohort. The frequencies of the ACE1 ID, DD, and II genotypes were 51%, 31%, and 18%, respectively. The frequency of the D allele was similar between the ICU and non-ICU groups (50.4% versus 49.6%). Older age and the presence of advanced stage radiologic abnormalities on admission were detected as independent predictors of ICU requirement. Conclusion: No effect of any ACE1 gene polymorphism on predicting ICU requirement was detected. To the best of our knowledge, this is the first study investigating the impact of ACE gene polymorphisms on clinical severity of COVID-19 in a Turkish cohort.
Anahtar Kelime:

Konular:
Fen > Tıp > Kalp ve Kalp Damar Sistemi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Yamamoto N, Ariumi Y, Nishida N, Yamamoto R, Bauer G, Gojobori T, et al. SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype. Gene 2020; 758: 144944. [Crossref]
  • 2. Saadat M. No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection. Clin Chem Lab Med 2020; 58: 1127-8. [Crossref]
  • 3. Bastug A, Bodur H, Erdogan S, Gokcinar D, Kazancioglu S, Kosovali BD, et al. Clinical and laboratory features of COVID-19: Predictors of severe prognosis. Int Immunopharmacol 2020; 88: 106950. [Crossref]
  • 4. Gómez J, Albaiceta GM, García-Clemente M, López-Larrea C, Amado-Rodríguez L, Lopez-Alonso I, et al. Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene 2020; 762: 145102. [Crossref]
  • 5. Zheng H, Cao JJ. Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019. Am J Pathol 2020; 190: 2013-7. [Crossref]
  • 6. Wang R, Alam G, Zagariya A, Gidea C, Pinillos H, Lalude O, et al. Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo. J Cell Physiol 2000; 185: 253-9. [Crossref]
  • 7. Sarangarajan R, Winn R, Kiebish MA, Bountra C, Granger E, Narain NR. Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers. J Racial Ethn Health Disparities 2021; 8: 973-80. [Crossref]
  • 8. Suryamohan K, Diwanji D, Stawiski EW, Gupta R, Miersch S, Liu J, et al. Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Commun Biol 2021; 4: 475. [Crossref]
  • 9. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization. Available from: URL: https://apps.who.int/iris/handle/10665/331446. [Crossref]
  • 10. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96: 2162-9. [Crossref]
  • 11. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-43. [Crossref]
  • 12. Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 2020; 108: 154262. [Crossref]
  • 13. Göker H, Aladağ Karakulak E, Demiroğlu H, Ayaz Ceylan ÇM, Büyükaşik Y, Inkaya AÇ, et al. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. Turk J Med Sci 2020; 50: 679-83. [Crossref]
  • 14. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-9. [Crossref]
  • 15. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6. [Crossref]
  • 16. Itoyama S, Keicho N, Quy T, Phi NC, Long HT, Ha LD, et al. ACE1 polymorphism and progression of SARS. Biochem Biophys Res Commun 2004; 323: 1124-9. [Crossref]
  • 17. Pati A, Mahto H, Padhi S, Panda AK. ACE deletion allele is associated with susceptibility to SARS-CoV-2 infection and mortality rate: An epidemiological study in the Asian population. Clin Chim Acta 2020; 510: 455-8. [Crossref]
  • 18. Matsuda A, Kishi T, Jacob A, Aziz M, Wang P. Association between insertion/deletion polymorphism in angiotensin-converting enzyme gene and acute lung injury/acute respiratory distress syndrome: a meta-analysis. BMC Med Genet 2012; 13: 76. [Crossref]
  • 19. Delanghe JR, Speeckaert MM, De Buyzere ML. COVID-19 infections are also affected by human ACE1 D/I polymorphism. Clin Chem Lab Med 2020; 58: 1125-6. [Crossref]
  • 20. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020; 382: 2441-8. [Crossref]
  • 21. American College of Cardiology. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. March 17, 2020. Available from: URL: https://www.acc.org/ latest -in -cardiology/ articles/2020/03/ 17/ 08/ 59/ hfsa -acc -aha -statement -addresses -concerns -re-using-raas-antagonists -in-covid-19.
  • 22. European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. March 13, 2020. Available from: URL: https:// www.escardio.org/Councils/Council-on-Hypertension-(CHT)/ News/ position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang.
APA BAŞTUĞ S, ÇAVDARLI B, BASTUG A, ŞENCAN İ, TUNCEZ E, ÇAKIR E, KEMİRTLEK N, SAKAR C, ERDEM D, GÜLEÇ CEYLAN G, TURAN I, KAZANCIOĞLU S, BODUR H (2022). Are angiotensin converting enzyme (ACE1/ ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A singlecenter cohort study. The Anatolian Journal of Cardiology, 26(2), 133 - 140. 10.5152/AnatolJCardiol.2021.502
Chicago BAŞTUĞ Serdal,ÇAVDARLI Büşranur,BASTUG Aliye,ŞENCAN İrfan,TUNCEZ Ebru,ÇAKIR Esra,KEMİRTLEK Nizamettin,SAKAR Cihad,ERDEM Deniz,GÜLEÇ CEYLAN GÜLAY,TURAN Işıl ÖZKOÇAK,KAZANCIOĞLU Sümeyye,BODUR Hürrem Are angiotensin converting enzyme (ACE1/ ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A singlecenter cohort study. The Anatolian Journal of Cardiology 26, no.2 (2022): 133 - 140. 10.5152/AnatolJCardiol.2021.502
MLA BAŞTUĞ Serdal,ÇAVDARLI Büşranur,BASTUG Aliye,ŞENCAN İrfan,TUNCEZ Ebru,ÇAKIR Esra,KEMİRTLEK Nizamettin,SAKAR Cihad,ERDEM Deniz,GÜLEÇ CEYLAN GÜLAY,TURAN Işıl ÖZKOÇAK,KAZANCIOĞLU Sümeyye,BODUR Hürrem Are angiotensin converting enzyme (ACE1/ ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A singlecenter cohort study. The Anatolian Journal of Cardiology, vol.26, no.2, 2022, ss.133 - 140. 10.5152/AnatolJCardiol.2021.502
AMA BAŞTUĞ S,ÇAVDARLI B,BASTUG A,ŞENCAN İ,TUNCEZ E,ÇAKIR E,KEMİRTLEK N,SAKAR C,ERDEM D,GÜLEÇ CEYLAN G,TURAN I,KAZANCIOĞLU S,BODUR H Are angiotensin converting enzyme (ACE1/ ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A singlecenter cohort study. The Anatolian Journal of Cardiology. 2022; 26(2): 133 - 140. 10.5152/AnatolJCardiol.2021.502
Vancouver BAŞTUĞ S,ÇAVDARLI B,BASTUG A,ŞENCAN İ,TUNCEZ E,ÇAKIR E,KEMİRTLEK N,SAKAR C,ERDEM D,GÜLEÇ CEYLAN G,TURAN I,KAZANCIOĞLU S,BODUR H Are angiotensin converting enzyme (ACE1/ ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A singlecenter cohort study. The Anatolian Journal of Cardiology. 2022; 26(2): 133 - 140. 10.5152/AnatolJCardiol.2021.502
IEEE BAŞTUĞ S,ÇAVDARLI B,BASTUG A,ŞENCAN İ,TUNCEZ E,ÇAKIR E,KEMİRTLEK N,SAKAR C,ERDEM D,GÜLEÇ CEYLAN G,TURAN I,KAZANCIOĞLU S,BODUR H "Are angiotensin converting enzyme (ACE1/ ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A singlecenter cohort study." The Anatolian Journal of Cardiology, 26, ss.133 - 140, 2022. 10.5152/AnatolJCardiol.2021.502